• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    EyePoint, Inc. - Common Stock (NQ:EYPT)

    14.39 +0.28 (+1.98%)
    Streaming Delayed Price Updated: 12:08 PM EDT, Apr 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about EyePoint, Inc. - Common Stock

    News headline image
    EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
    From EyePoint Pharmaceuticals, Inc.
    Via GlobeNewswire
    R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
    EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
    Via FinancialNewsMedia
    EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equities by Percentage Gain on 4/21
    Via Investor Brand Network
    Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) Leading the Way in Monday Trading Based on Percentage Gain
    Via Investor Brand Network
    News headline image
    EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Establishment and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Intuit and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    NASDAQ:EYPT Investor Alert: Investigation over Potential Securities Laws Violations by EyePoint Pharmaceuticals, Inc. ↗
    San Diego, CA -- (SBWIRE) -- 11/02/2022 -- EyePoint Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
    Via SBWire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating Vintage Wine, Flowserve, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating FedEx, Cantaloupe, Compass, and EyePoint and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, F45 Training, and PROG and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    News headline image
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
    From The Schall Law Firm
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.